<?xml version='1.0' encoding='utf-8'?>
<document id="29695615"><sentence text="Metabolism of a 5HT6 Antagonist, 2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole (SAM-760): Impact of Sulfonamide Metabolism on Diminution of a Ketoconazole-Mediated Clinical Drug-Drug Interaction."><entity charOffset="33-100" id="DDI-PubMed.29695615.s1.e0" text="2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole" /><entity charOffset="102-109" id="DDI-PubMed.29695615.s1.e1" text="SAM-760" /><entity charOffset="122-133" id="DDI-PubMed.29695615.s1.e2" text="Sulfonamide" /><entity charOffset="164-176" id="DDI-PubMed.29695615.s1.e3" text="Ketoconazole" /><pair ddi="false" e1="DDI-PubMed.29695615.s1.e0" e2="DDI-PubMed.29695615.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29695615.s1.e0" e2="DDI-PubMed.29695615.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29695615.s1.e0" e2="DDI-PubMed.29695615.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29695615.s1.e0" e2="DDI-PubMed.29695615.s1.e3" /><pair ddi="false" e1="DDI-PubMed.29695615.s1.e1" e2="DDI-PubMed.29695615.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29695615.s1.e1" e2="DDI-PubMed.29695615.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29695615.s1.e1" e2="DDI-PubMed.29695615.s1.e3" /><pair ddi="false" e1="DDI-PubMed.29695615.s1.e2" e2="DDI-PubMed.29695615.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29695615.s1.e2" e2="DDI-PubMed.29695615.s1.e3" /></sentence><sentence text="SAM-760 [(2-methyl-1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole)], a 5HT6 antagonist, was investigated in humans for the treatment of Alzheimer's disease"><entity charOffset="0-77" id="DDI-PubMed.29695615.s2.e0" text="SAM-760 [(2-methyl-1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-benzo[d]imidazole" /></sentence><sentence text=" In liver microsomes and recombinant cytochrome P450 (P450) isozymes, SAM-760 was predominantly metabolized by CYP3A (âˆ¼85%)" /><sentence text=" Based on these observations and an expectation of a 5-fold magnitude of interaction with moderate to strong CYP3A inhibitors, a clinical DDI study was performed" /><sentence text=" In the presence of ketoconazole, the mean Cmax and area under the plasma concentration-time curve from time zero extrapolated to infinite time values of SAM-760 showed only a modest increase by 30% and 38%, respectively"><entity charOffset="20-32" id="DDI-PubMed.29695615.s5.e0" text="ketoconazole" /></sentence><sentence text=" In vitro investigation of this unexpectedly low interaction was undertaken using [14C]SAM-760"><entity charOffset="82-94" id="DDI-PubMed.29695615.s6.e0" text="[14C]SAM-760" /></sentence><sentence text=" Radiometric profiling in human hepatocytes confirmed all oxidative metabolites previously observed with unlabeled SAM-760; however, the predominant radiometric peak was an unexpected polar metabolite that was insensitive to the pan-P450 inhibitor 1-aminobenzotriazole"><entity charOffset="248-268" id="DDI-PubMed.29695615.s7.e0" text="1-aminobenzotriazole" /></sentence><sentence text=" In human hepatocytes, radiometric integration attributed 43% of the total metabolism of SAM-760 to this non-P450 pathway" /><sentence text=" Using an authentic standard, this predominant metabolite was confirmed as benzenesulfinic acid"><entity charOffset="75-95" id="DDI-PubMed.29695615.s9.e0" text="benzenesulfinic acid" /></sentence><sentence text=" Additional investigation revealed that the benzenesulfinic acid metabolite may be a novel, nonenzymatic, thiol-mediated reductive cleavage of an aryl sulfonamide group of SAM-760"><entity charOffset="44-64" id="DDI-PubMed.29695615.s10.e0" text="benzenesulfinic acid" /><entity charOffset="106-111" id="DDI-PubMed.29695615.s10.e1" text="thiol" /><entity charOffset="146-162" id="DDI-PubMed.29695615.s10.e2" text="aryl sulfonamide" /><pair ddi="false" e1="DDI-PubMed.29695615.s10.e0" e2="DDI-PubMed.29695615.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29695615.s10.e0" e2="DDI-PubMed.29695615.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29695615.s10.e0" e2="DDI-PubMed.29695615.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29695615.s10.e1" e2="DDI-PubMed.29695615.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29695615.s10.e1" e2="DDI-PubMed.29695615.s10.e2" /></sentence><sentence text=" We also determined the relative contribution of P450 to the metabolism of SAM-760 in human hepatocytes by following the rate of formation of oxidative metabolites in the presence and absence of P450 isoform-specific inhibitors" /><sentence text=" The P450-mediated oxidative metabolism of SAM-760 was still primarily attributed to CYP3A (33%), with minor contributions from P450 isoforms CYP2C19 and CYP2D6" /><sentence text=" Thus, the disposition of [14C]SAM-760 in human hepatocytes via novel sulfonamide metabolism and CYP3A verified the lower than expected clinical DDI when SAM-760 was coadministered with ketoconazole"><entity charOffset="26-38" id="DDI-PubMed.29695615.s13.e0" text="[14C]SAM-760" /><entity charOffset="70-81" id="DDI-PubMed.29695615.s13.e1" text="sulfonamide" /><entity charOffset="186-198" id="DDI-PubMed.29695615.s13.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.29695615.s13.e0" e2="DDI-PubMed.29695615.s13.e0" /><pair ddi="false" e1="DDI-PubMed.29695615.s13.e0" e2="DDI-PubMed.29695615.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29695615.s13.e0" e2="DDI-PubMed.29695615.s13.e2" /><pair ddi="false" e1="DDI-PubMed.29695615.s13.e1" e2="DDI-PubMed.29695615.s13.e1" /><pair ddi="false" e1="DDI-PubMed.29695615.s13.e1" e2="DDI-PubMed.29695615.s13.e2" /></sentence><sentence text="" /></document>